Condition: Intradialytic Hypotension · Sponsor: Centre Hospitalier de Bethune
During intermittent hemodialysis (IHD), the occurrence of intradialytic hemodynamic instability (IHI) is frequent in ICU and impacted morbidity and mortality. Bicarbonate dialysate buffer improves hemodynamic tolerance compared to acetate dialysate buffer. However, bicarbonate dialysate buffer still contains a lower concentration of acetate, which could contribute to hemodynamic instability. Recently, citrate-based dialysate in bicarbonate hemodialysis instead of acetate have been proposed. They have the appropriate authorizations for routine use. The aim of this study is to compare acetate- vs citrate-based dialysate in terms of hemodynamic tolerance and effectiveness.
This description comes directly from the study's public registry record.
Martin GÉRARD · 03.21.64.44.44 · mgerard@ch-bethune.fr
Christophe VINSONNEAU · 03.21.64.44.44 · cvinsonneau@ch-bethune.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Béthune | Béthune, France | Recruiting |
| CHU | Caen, France | Recruiting |
| Centre Hospitalier Universitaire de Dijon | Dijon, France | Recruiting |
| CHRU Nancy | Nancy, France | Recruiting |
| CHU de ROUEN | Rouen, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05936710